Corazon Appoints New President & CEO, Announces Human Clinical Trials Before Year's End.Business Editors/Health & Medical Writers MENLO PARK, Calif.--(BUSINESS WIRE)--Nov. 18, 2002 Corazon Technologies, developer of proprietary technologies designed to help physicians manage calcific calcific /cal·cif·ic/ (-ik) forming lime. calcific forming lime. cardiovascular and valvular valvular /val·vu·lar/ (val´vu-ler) pertaining to, affecting, or of the nature of a valve. val·vu·lar adj. Relating to, having, or operating by means of valves or valvelike parts. disease during interventional and surgical procedures, today reported several new advancements in the company's progression. New President & CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. Named In an effort to help Corazon take its technology from the research phase to commercialization, the Board of Directors has promoted Geoffrey D. Dillon to President and CEO. Geoff joined Corazon in January of 2002 as the Executive Vice President. In June, he was named Chief Operating Officer Chief Operating Officer (COO) The officer of a firm responsible for day-to-day management, usually the president or an executive vice-president. . Prior to joining Corazon, Geoff served as Vice President of Global Sales and Marketing at CardioThoracic Systems, Inc., and spent two years as Vice President of Sales and Marketing for the Cardiovascular Systems Division of Quest Medical. "Geoff has done an outstanding job of leading Corazon from a research-oriented company to a development-stage company," comments Richard M. Ferrari, Chairman of Corazon's Board of Directors. Human Clinical Trials Scheduled The company intends to market devices that dissolve and remove calcific mineral deposits from blocked coronary arteries and calcified Calcified Hardened by calcium deposits. Mentioned in: Heart Valve Repair heart valves. This will enable less-invasive treatments for clearing blockages, and help restore the functionality of heart valves. In line with its strategy to reposition for commercialization, the company also reported that it will begin a human feasibility clinical trial for its aortic valve program before the year's end. The initial clinical trial will take place in Brazil. "The company has already validated its technology during exhaustive bench tests, animal tests, and a small European human trial," explains Geoff. "Now, it's time to leverage that 'proof of concept' by delivering to physicians innovative technology that has the potential to profoundly change the way calcific cardiovascular disease is treated." During the first quarter of 2003, Corazon will begin raising funds to help finance its FDA clearance process and preparation for International and U.S. commercialization. Corazon was founded in December 1998 and is headquartered in Menlo Park, California Menlo Park is a city in San Mateo County, California in the United States of America. It is located at latitude 37°29' North, longitude 122°9' East. Menlo Park had 30,785 inhabitants as of the 2000 U.S. Census. . The company's technology is expected to revolutionize heart valve repair Heart Valve Repair Definition Heart valve repair is a surgical procedure used to correct a malfunctioning heart valve. Repair usually involves separating the valve leaflets (the one-way "doors" of the heart valve which open and close to and the treatment of coronary artery disease coronary artery disease, condition that results when the coronary arteries are narrowed or occluded, most commonly by atherosclerotic deposits of fibrous and fatty tissue. . Corazon recently completed enrollment and acute follow up in a small European clinical trial to evaluate the safety of its technologies in the treatment of arterial disease. For more information about Corazon Technologies, please visit the company's Web site a www.corazon-inc.com. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion